Abstract
Regulation of intracellular Ca2+ ([Ca2+]i) plays a key role in obesity, insulin resistance and hypertension, and [Ca2+]i disorders may represent a fundamental factor linking these three conditions. We have shown insulin to be a direct vasodilator, attenuating voltage-gated Ca2+ influx and stimulating Ca2+-ATPase transcription via a glucose-6-phosphate response element. These result in a net decrease in [Ca2+]i and thereby decrease vascular resistance, while these effects are blunted in insulin resistance, leading to increased vascular resistance. Consistent with this concept, pharmacological amplification of peripheral insulin sensitivity results in reduced arterial pressure. While insulin regulates [Ca2+]i, Ca2+ also regulates insulin signaling, as increasing [Ca2+]i impairs insulin signaling in some systems, possibly due to Ca2+ inhibition of insulin-regulated dephosphorylation. Finally, in recent studies of the mouse agouti gene, we have also demonstrated increased [Ca2+]i to play a key role in adipocyte lipogenesis, as follows. We have found dominant agouti mutants to exhibit increased [Ca2+]i in most tissues, leading to increased vascular reactivity and insulin resistance in vascular smooth muscle and skeletal muscle cells, respectively. Further, we have found recombinant agouti protein to directly increase [Ca2+]i in a variety of cells, including murine and human adipocytes, and to stimulate both the expression and activity of adipocyte fatty acid synthase and increase triglyceride accumulation in a Ca2+-dependent manner. These effects can be mimicked by stimulation of Ca2+ influx and blocked by Ca2+ channel inhibition, while treatment of mice with a Ca2+ antagonist attenuates agouti-induced obesity. Since humans express agouti in adipose tissue, it may similarly exert paracrine effects on [Ca2+]i and thereby stimulate de novo lipogenesis and promote obesity. Thus, Ca2+ signaling represents a target for therapeutic intervention in obesity as well as hypertension and insulin resistance. (Mol Cell Biochem 188: 129–136, 1998)
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Reaven G: Role of insulin resistance in human disease. Diabetes 37: 1595–1607, 1988
Zemel MB: Insulin resistance, obesity and hypertension: An overview. J Nutrl 25: 1715S–1717S, 1995
Rocchini AP: Insulin resistance and blood pressure regulation in obese and non-obese subjects. Hypertension 17: 837–842, 1991
Rowe JW, Young JB, Minaker KL, Stevens AL, Palotta, Landsberg L: Effect of insulin and glucose infusion on sympathetic nervous system activity in normal man. Diabetes 30: 219–225, 1981
Anderson EA, Hoffman RP, Balor TW, Sinkey CA, Mark AL: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87: 2246–2252, 1991
Anderson EA, Balor TW, Hoffman RP, Sinkey CA, MarkAL: Increases sympathetic activity but not blood pressure in borderline hypertensive humans. J Clin Invest 89: 621–627, 1992
Zemel MB, Penler JD, Sowers JR, Simpson L: Hypertension in insulin-resistant Zucker obese rats is independent of sympathetic neural support. Am J Physiol 262: E368–E371, 1992
Zemel MB, Reddy S, Shehin S, Lockerte W, Sowers JR: Vascular reactivity in Zucker obese rats: Role of insulin resistance. JVasc Med Biol 2: 81–85, 1990
Zemel MB, Reddy S, Sowers JR: Insulin attenuation of vasoconstrictor responses to phenylephrine in Zucker lean and obese rats. Am J Hypertension 4: 537–539, 1991
Zemel MB, Johnson BA, Ambrozy SA: Insulin-stimulated vascular relaxation: Role of Ca2+-ATPase. Am J Hypertension 5: 637–641, 1992
Kim YC, Zemel MB: Insulin increases vascular smooth muscle recovery from intracellular calcium loads. Hypertension 22: 74–77, 1993
Kahn AM, Seidel CL, Allen JC, O’Neil RG: Insulin reduces contraction and intracellular calcium concentration in vascular smooth muscle. Hypertension 22: 735–742, 1993
Juncos LA, Ito S, Carretero OA: Disparate effects of insulin on isolated rabbit afferent and efferent arterioles. Hypertension 20: 403, 1992
Hall JE, Coleman TG, Mizelle HL: Does chronic hyperinsulinemia cause hypertension. Am J Hypertension 2: 171–173, 1989
Brands MW, Mizelle HL, Gaillard CA, Hildebrandt DA, Hall JE: The hemodynamic response to chronic hyperinsulinemia in conscious dogs. Am J Hypertension 4: 164–168, 1991
Morgan DA, Ray CA, Balon TW, Mark AL: Metformin increases insulin sensitivity and lowers arterial pressure in spontaneously hypertensive rats. Hypertension 20: 421, 1992
Dubey RK, Zhang HY, Reddy SR, Buegehold MA, Kotchen TA: Pioglitazone attenuates hypertension and growth of renal arteriolar smooth muscle cells in rats. Am J Phsyiol 265: R276–R732, 1993
Pershadsingh HA, Szollosi J, Bensorn S, Hyun WC, Feurstein BG, Kurtz TW: Effect of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 21: 1020–1023, 1993
Cooper DR, Foote J, Petch C, SchofieldPM: Chronic effects of glucose on insulin signaling in A-10 vascular smooth muscle cells. Arch Biochem Biophys 302: 490–498, 1993
Ban, WJ, Abel MA, Zemel MB: Insulin regulation of vascular smooth muscle glucose transport in insulin-sensitive and resistant rats. Hor Metab Res 28: 271–275, 1996
Zemel MB: Insulin resistance vs. Hyperinsulinemia in hypertension: Insulin regulation of Ca2+ transport and Ca2+ regulation of insulin sensitivity. J Nutr 125: 1738S–1743S, 1995
Standley PR, Zhang F, Ram JL, Zemel MB, Sowers JR: Insulin attenuates vasopressin-induced calcium transients and voltage-dependent calcium current in rat vascular smooth muscle cells. J Clin Invest 88: 1230–1236, 1991
Touyz RM, Tolloczko B, Schiffrin EL: Insulin attenuates agonist-evoked calcium transients in vascular smooth muscle cells. Hypertension 23(Suppl. I): 125–128, 1994
Kahn AM, Seidel CL, Allen JC, O’Neil RG: Insulin reduces contraction and intracellular calcium concentration in vascular smooth muscle. Hypertension 22: 735–742, 1993
Levy J, Zemel MB, Sowers JR: Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension. Am J Med 87(Suppl. 6A): 155–165
Zemel MB, Bedford BA, Zemel PC, Marwah O, Sowers JR: Altered cation transport in non-insulin-dependent diabetics: Effects of dietary calcium. J Hypertension 6(Suppl. 4): S228–S230
Shehin SE, Sowers JR, Zemel MB: Impaired vascular smooth muscle 45Ca efflux and hypertension in Zucker obese rats. J Vasc Med Biol 1: 278–282, 1989
Abel MA, Zemel MB: Impaired recovery of vascular smooth muscle intracellular calcium following agonist stimulation in insulin resistant (Zucker obese) rats. Am J Hypertension 6: 500–504, 1993
Reddy S, Shehin S, Sowers JR, Dardas G, Zemel MB: Aortic 45Ca flux and blood pressure regulation in streptozotocin-induced diabetic rats. J Vasc Med Biol 2: 47–50, 1990
Zemel MB, Iannucci A, Moore JW: Role of insulin in regulating vascular smooth muscle Ca2+-ATPase expression. J Vasc Med Biol 4: 79–84
Kim YC, Zemel MB: Insulin stimulation of intracellular free Ca2+ recovery and Ca2+-ATPase gene expression in cultured vascular smooth muscle cells: Role of glucose-6-phosphate. Biochem J 311: 555–559, 1995
Draznin B, Sussman K, Kao M, Lewis D, Sherman N: The existence of an optimal range of cytosolic free calcium for insulin-stimulated glucose transport in rat adipocytes. J Biol Chem 262: 14385–14388, 1987
Draznin B: Cytosolic calcium and insulin resistance. Am J Kidney Dis 21(Suppl. 3): 32–38, 1993
Segal S, Lloyd S, Sherman N, Sussman KE, Draznin B: Postprandial changes in cytosolic free calcium and glucose uptake in adipocytes in obesity and non-insulindependent diabetes mellitus. Horm Res 34: 39–44, 1990
Epstein M, Sowers JR: Diabetes mellitus and hypertension. Hypertension 19: 403–418, 1992
Bursztyn M, Raz I, Mekler J, Ben-Ishay D: Nitrendipine improves glucose tolerance and deoxyglucose uptake in hypertensive rats. Hypertension 23: 1051–1053, 1994
Beer NA, Jakubowicz DJ, Beer RM, Arocha IR, Nestler JE: Effects of nitrendipine on glucose tolerance and serum insulin and dehydro-epiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocrinology 76: 178–183, 1993
Beer NA, Jakubowicz DJ, Beer RM: Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese hypertensive men and women. J Clin Endocrinology 79: 1077–1081, 1994
Byyny RL, LoVerde M, Mitchell W, Draznin B: Cytosolic calcium and insulin resistance in elderly patients. Am J Hypertension 5: 459–464, 1992
Harano Y, Dageyama A,Hirose J, Asakura Y, Yokota T, Ikebuchi M, Suzuki M, Omae T: Improvement of insulin sensitivity for glucose metabolism with the longacting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism 44: 315–319, 1995
Draznin B, Lewis D, HoulderN, Sherman N, Adamo M, Garvey WT, LeRoigh D, Sussman K: Mechanism of insulin resistance induced by sustained levels of cytosolic free calcium in rat adipocytes. Endocrinology 125: 2341–2349, 1989
Dohm GL, Elton CW, Friedman JE, Pilch PF, Pories WJ, Atkinson SM Jr, Caro JF: Decreased expression of glucose transporter in muscle from insulin resistant patients. Am J Physiol 260: E459–E463, 1991
Pederson O, Bak JF, Andersen PH, Lund S, Moller DE, Flier JS, Kahn BB: Evidence altered expression of GLUT1 or GLUTS in skeletal muscle of patients with obesity or NIDDM. Diabetes 39: 865–870, 1990
Handberg A, Vaag A, Damsba P, Beck-Nielsen H, Vinten J: Expression of insuilnregulatable glucose transporters in skeletal muscle from type 2 (non-insulindependent) diabetic patients. Diabetologia 33: 625–627, 1990
Begum N, Leitner W, Reusch J E-B, Sussman KE, Draznin B: Glut-4 phosphorylation and its intrinsic activity. J Biol Chem 268: 3352–3356, 1993
Begum N, Sussman KE, Draznin B: Calcium-induced inhibition of phosphoserine phosphatase in insuiln target cells is mediated by the phosphorylation and activation of inhibitor 1. J Biol Chem 267: 5959–5963
Kida Y, Esposito-Del Puente A, Bogardus C, Mott DM: Insulin resistance is associated with reduced fasting and insulin-stimulated glycogen synthase phosphatase activity in human skeletal muscle. J Clin Invest 85: 476–481, 1990
Freidenberg GR, Henry RR, Klein HH, Reichart DR, Olefsky JM: Decreased kinase activity of insulin receptors from adipocytes of non-insulin-dependent diabetic subjets. J Clin Invest 79: 240–250, 1987
Dent P, Lavoinne A, Nakielny S, Caudwell FB: The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348: 302–308, 1990
Munshi HG, Burks DJ, Joyal JL, White MF, Sacks DB: Ca2+ regulates calmodulin binding to IQ motifs in IRS-1. Biochemistry 35: 15883–15889, 1996
Yen TT, Gill AM, Frigeri LG, Barsh GS, Wolff GL: Obesity, diabetes and neoplasia in yellow A vy/-mice: Ectopic expression of the agouti gene. FASEB J 8: 479–488, 1994
Zemel MB, Moore WJ, Rahman MK, Moustaid N: Diazoxide antagonism of glybenclamide-induced Ca2+ signaling and lipogenic activity in 3T3-L1 adipocytes. Obesity Res 4: 28s, 1996
Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA: Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest 82: 1848–1852, 1988
Bultman SJ, Michaud EJ, Woychik RP. Molecular characterization of the mouse agouti locus. Cell 71: 1195–1204, 1992
Michaud EJ, Bultman SJ, Stubbs LJ, Woychik RP: The embryonic letality of homozygous lethal yellow mice (A y/A y) is associated with the disruption of a novel RNA-binding protein. Genes Dev 7: 1203–1213, 1993
Michaud EJ, Vugt MJ, Bultman SJ, Sweet HO, Davisson MT, Woychik RP: Differential expression of a new dominant mutant agouti allele (A iapy) is correlated with methylation state and is influenced by parental lineage. Genes Dev 8: 1463–1472, 1994
Klebig ML, Wilkinson JE, Geisler JG, Woychik RP: Ectopic expression ofthe agouti gene in transgenic mice causes obesity, features of type II, and yellow fur. Proc Nat Acad Sci USA 92: 4728–4732, 1995
Zemel MB, Kim JH, Woychik RP, Michaud EJ, Kadwell SH, Patel IR, Wilkison WO: Agouti regulation of intracellular calcium: Role in the insulin resistance of viable yellow mice. Proc Nat Acad Sci USA 92: 4733–4737, 1995
Kim JH, Kiefer LL, Woychik RP, Wilkison WO, Truesdale A, Ittoop O, Willard D, Nichols J, Zemel MB: Agouti regulation of intracellular calcium: role of melanocortin receptors. Am J Physiol 272: E379–E384, 1997
Wolff GL: Growth of inbred yellow (A y/a) and non-yellow (a/a) mice in parabiosis. Genetics 48: 1041–1058, 1963
Johnson PR, Hirsch J: Cellularity of adipose depot in six strains of genetically obese mice. J Lipid Res 13: 2–11, 1972
Jones BH, Kim JH, Zemel MB, Woychik RP, Michaud EJ, Wilkison WO, Moustaid N: Upregulation of adipocyte metabolism by agouti protein: Possible paracrine actions in yellow mouse obesity. Am J Physiol 270: E192–E196, 1996
Claycombe KH, Jones BH, Standridge MK, Wilkison WO, Zemel MB, Guo YS, Moustaid N: Transcriptional regulation ofthe adipocyte fatty acid synthase gene by the agouti gene product: Interaction with insulin. FASEB J 11:A352, 1997
Zemel MB, Kim JH, Jones BH, Moore JW, Woychik RP, Moustaid N, Wilkison WO: Agouti gene product regulation of intracellular free calcium results in stimulation of fatty acid synthase. Obesity Res 3: 338s, 1995
Moore JW, Willard D, Moustaid N, Wilkison WO, Zemel MB: Role of intracellular calcium in agouti and insulin modulation of fatty acid synthase. FASEB J 10: A187, 1996
Kwon HY, Bultman SJ, Loffler C, Chen WJ, Furdon PJ, Powell JG, Usala AL, Wilkison W, Hansmann I, Woychik RP: Molecular structure and chromosomal mapping of the human homologue of the agouti gene. Proc Nat Acad Sci USA 91: 9760–9764, 1994
Kim JH, Mynatt RL, Moore JW, Woychik RP, Moustaid N, Wilkison WO and Zemel MB: The effects of calcium channel blockade on agouti-induced obesity. FASEB J 10: 1646–1652
Xue B, Wilkison WO, Mynatt RL, Moustaid N, Zemel MB: The agouti gene product stimulates pancreatic ² cell Ca2+ signaling and insulin release. FASEB J 11: A320, 1997
Mynatt RL, Miltenberger RJ, Klebig ML, Zemel MB, Wilkinson JE, Wilkison WO, Woychik RP: Combined effects of insulin treatment and adipose tissue-specific agouti expression on the development of obesity. Proc Nat Acad Sci USA 94: 919–922, 1997
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Zemel, M.B. (1998). Nutritional and endocrine modulation of intracellular calcium: Implications in obesity, insulin resistance and hypertension. In: Pierce, G.N., Izumi, T., Rupp, H., Grynberg, A. (eds) Molecular and Cellular Effects of Nutrition on Disease Processes. Developments in Molecular and Cellular Biochemistry, vol 26. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5763-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5763-0_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7641-5
Online ISBN: 978-1-4615-5763-0
eBook Packages: Springer Book Archive